Analysts Offer Predictions for ALX Oncology FY2028 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Stock analysts at HC Wainwright decreased their FY2028 earnings per share estimates for ALX Oncology in a note issued to investors on Friday, November 8th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $1.43 per share for the year, down from their previous estimate of $1.44. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($3.04) per share.

Several other brokerages also recently commented on ALXO. UBS Group dropped their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Stifel Nicolaus restated a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Monday, August 12th. Finally, Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, ALX Oncology has an average rating of “Moderate Buy” and a consensus price target of $12.50.

ALX Oncology Stock Down 4.0 %

Shares of NASDAQ:ALXO opened at $1.45 on Monday. The stock’s 50-day moving average price is $1.76 and its two-hundred day moving average price is $5.96. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06. ALX Oncology has a 12-month low of $1.34 and a 12-month high of $17.83. The firm has a market cap of $76.37 million, a price-to-earnings ratio of -0.49 and a beta of 1.03.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Swiss National Bank bought a new stake in shares of ALX Oncology during the 1st quarter valued at $493,000. Inspire Investing LLC acquired a new stake in shares of ALX Oncology in the first quarter valued at about $370,000. Vanguard Group Inc. increased its stake in shares of ALX Oncology by 4.3% in the first quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after buying an additional 64,055 shares during the period. CANADA LIFE ASSURANCE Co acquired a new stake in ALX Oncology during the first quarter worth approximately $27,000. Finally, EntryPoint Capital LLC bought a new stake in ALX Oncology during the 1st quarter valued at $32,000. 97.97% of the stock is currently owned by institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.